NCT03050086

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: BioPharmX, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.

Conditions

• Moderate to Severe Papulopustular Rosacea

Interventions

Type	Name	Description
DRUG	BPX-04 1% minocycline topical gel	once daily administration of topical minocycline gel to face
DRUG	BPX-04 2% minocycline topical gel	once daily administration of topical minocycline gel to face
DRUG	BPX-04 vehicle topical gel	once daily administration of topical minocycline gel to face

Timeline

• Start date: 2017-03-29
• Primary completion: 2018-06-19
• Completion: 2018-06-19
• First posted: 2017-02-10
• Last updated: 2019-01-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study